English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background: Intranasal glucocorticoids effectively and safely alleviate the symptoms of allergic rhinitis, but treatment options from this drug class are still limited for the Japanese pediatric population. Objective: To evaluate the efficacy and tolerability of mometasone furoate nasal spray (MFNS) at a oncedaily dosage compared with a placebo spray (placebo) in Japanese children with perennial allergic rhinitis (PAR). Methods: In this randomized, double-blind, multicenter study, subjects aged 5~15 years with PAR were randomly assigned to MFNS or the placebo for 2 weeks. The once-daily morning dosage of MFNS was 100 μg (50 μg per nostril) in subjects aged 5~11 years and 200 μg (100 μg per nostril) in those aged 12~15 years. The primary end point consisted of change from baseline in the total nasal symptom score (TNSS) at week 2 or discontinuation. Other efficacy end points included investigator-assessed measures of individual nasal symptoms, interference with daily activities, and global improvement. Results: Of the 333 randomized subjects, 330 completed the full 2 weeks of treatment. The between-treatment difference in TNSS at week 2 or discontinuation indicated the superiority of MFNS vs the placebo (P<0.0001). Scores for individual symptoms, interference with daily activities, and global improvement were significantly superior with MFNS vs the placebo at week 1 and week 2 or discontinuation. The overall incidence of adverse events was similar between MFNS (30.5%) and the placebo (36.3%), and all adverse events were mild to moderate. Conclusions: MFNS provided effective and rapid relief for PAR in a Japanese pediatric population while exhibiting tolerability similar to that of the placebo.

jibi inkōka rinshō. hosatsu/jibi inkoka rinsho. hosatsu

Multicenter, Double-blind, Randomized, Placebo-controlled Study on Mometasone Furoate Nasal Spray in Japanese Pediatric Subjects with Perennial Allergic Rhinitis